Not an actual patient.

28 DAYS1

  • Recommended dose: 300 mg infusion every 4 weeks
  • No premedication is required prior to infusion but may be administered based upon clinical judgment
  • Postinfusion observation: If no evidence of hypersensitivity reaction is observed after the first 12 infusions, a 1-hour postinfusion observation period is no longer required and is according to clinical judgment
    • If postinfusion observation is no longer required, total appointment time may be reduced by up to 50%
    • Total appointment time = infusion + observation
  • How supplied: 300 mg in a 15 mL, sterile, single-dose vial
    • Colorless, clear to slightly opalescent solution for dilution prior to IV infusion

Remember: Only orders from infusion centers and certified pharmacies enrolled in and authorized by the TOUCH® Prescribing Program will be processed. Contact Biogen at

Not actual size.


Refrigerate between 36ºF and 46ºF (2ºC and 8ºC)

Do not use TYSABRI beyond the expiration date printed on the carton or vial label

Do not shake or freeze

Protect from light

If not used immediately, store the diluted TYSABRI solution for infusion between 36°F and 46°F (2°C and 8°C)

TYSABRI solution for infusion must be administered within 48 hours of preparation


Follow 4 steps for dilution:

The final dosage solution has a concentration of 2.6 mg/mL. If TYSABRI is not infused immediately, see “Storage” instructions above.


  • Infuse TYSABRI 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP, over ~1 hour (infusion rate
    ~5 mg/minute)
    • Allow solution to warm to room temperature prior to infusion
    • Do not administer TYSABRI as an IV push or bolus injection
    • After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP
  • Observe patients during the infusion and for 1 hour after the infusion is complete for the first 12 infusions
    • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction
    • For patients who have shown no evidence of a hypersensitivity reaction, postinfusion observation is according to clinical judgment from the 13th infusion onward
  • Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI

Patient Reminders

Remind your patients to:

  • Read the Medication Guide before starting TYSABRI and before each TYSABRI infusion
  • Tell all of their HCPs that they are receiving TYSABRI
  • Follow up with their prescriber regularly1:
    • 3 and 6 months after the first infusion
    • Every 6 months thereafter
    • For at least 6 months after discontinuing TYSABRI
  • Continue to look for new signs and symptoms suggestive of PML for ~6 months after discontinuation1
  • Inform HCPs about any new medications2
  • Discuss new/worsening medical problems1
  • Request any additional support